1. Clinical & Scientific Overview
Intravenous Dextrose (25% / 50%) (TIP-MED-000289, Reference Code [4.24]-C19) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Rescue (Schedule H | NLEM 2022 | EMERGENCY).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Co-indexed constituent under primary monograph [4.24] (Glucagon & Oral / Intravenous Dextrose (Acute Severe Hypoglycaemia Protocol)). Representative Indian Market Examples (Edition 2.7 Ch 04 [4.24], p. 56): Glucagon: GlucaGen HypoKit 1 mg (Novo Nordisk). Oral Glucose: Glucon-D, Dexorange Glucose Tablets. IV Dextrose: 25% Dextrose (25D — 25 g/100mL), 10% Dextrose (10D) — Strengths & Dosage Forms: GlucaGen HypoKit: 1 mg (1 IU) lyophilised powder + 1 mL sterile water syringe for IM/SC injection. IV Ampoules/Bottles: 25% Dextrose (100 mL), 50% Dextrose (50 mL)
GlucaGen HypoKit: 1 mg (1 IU) lyophilised powder + 1 mL sterile water syringe for IM/SC injection. IV Ampoules/Bottles: 25% Dextrose (100 mL), 50% Dextrose (50 mL)
3. Mechanism of Action & Pharmacodynamics
Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Rescue (Schedule H | NLEM 2022 | EMERGENCY) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Rescue (Schedule H | NLEM 2022 | EMERGENCY) for Emergency reversal of severe hypoglycaemia (capillary blood glucose <54–70 mg/dL with neuroglycopenia, confusion, seizures, or unconsciousness) in patients on Insulin or Sulfonylureas.
4. Therapeutic Indications & Evidence-Supported Uses
- Emergency reversal of severe hypoglycaemia (capillary blood glucose <54–70 mg/dL with neuroglycopenia, confusion, seizures, or unconsciousness) in patients on Insulin or Sulfonylureas
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Conscious Patient (Rule of 15): 15–20 g fast-acting pure oral glucose (3–4 heaped teaspoons of Glucon-D in water), recheck CBG at 15 min, repeat if <70 mg/dL, then give complex carb snack. Unconscious / Unable to Swallow: Glucagon 1 mg IM/SC into anterolateral thigh (0.5 mg if child <25 kg). Hospital IV: 25% Dextrose 50–100 mL (12.5–25 g) slow IV push, followed by 10% Dextrose infusion
Administration & Meal Timing: Administer immediately upon recognition of hypoglycaemia; once consciousness returns (10–15 min after Glucagon), MUST give oral carbohydrate snack to replenish depleted liver glycogen! | STAT Emergency Rescue
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [4.24].
Renal & Hepatic: In CKD or cirrhosis with Sulfonylurea hypoglycaemia, always admit for continuous 10% IV Dextrose monitoring
Renal & Hepatic: In CKD or cirrhosis with Sulfonylurea hypoglycaemia, always admit for continuous 10% IV Dextrose monitoring
Renal & Hepatic: In CKD or cirrhosis with Sulfonylurea hypoglycaemia, always admit for continuous 10% IV Dextrose monitoring
7. Contraindications, Precautions & High-Risk Warnings
- NEVER pour oral liquids, honey, or sugar water into the mouth of an unconscious or seizing patient (aspiration asphyxiation!). Glucagon is INEFFECTIVE in starvation, chronic alcoholism, adrenal insufficiency, or severe cirrhosis because hepatic glycogen stores are already depleted (use IV Dextrose!)
Key Clinical Precautions: Renal & Hepatic: In CKD or cirrhosis with Sulfonylurea hypoglycaemia, always admit for continuous 10% IV Dextrose monitoring
8. Adverse Effects Profile
- Nausea and vomiting (very common upon waking after Glucagon injection — place unconscious patient in lateral recovery position!), transient tachycardia/BP rise
- Rebound recurrent hypoglycaemia if follow-up oral carbohydrate meal is omitted after Glucagon wears off (half-life 20–30 min); thrombophlebitis/extravasation necrosis with 25%/50% IV Dextrose
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Beta-blockers blunt the hyperglycaemic response to Glucagon and cause transient hypertension; Glucagon potentiates Warfarin anticoagulant effect
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [4.24].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Teach family members of every T1DM and high-risk Insulin/SU patient how to reconstitute GlucaGen HypoKit, inject into the outer thigh, turn the patient onto their side, and give a biscuit/sandwich as soon as they wake up
- Meal & Clock Timing Instruction: Administer immediately upon recognition of hypoglycaemia; once consciousness returns (10–15 min after Glucagon), MUST give oral carbohydrate snack to replenish depleted liver glycogen! (STAT Emergency Rescue)
- Missed Dose Protocol: Not applicable (emergency rescue)
- Geriatric Dispensing Pearl: Any Sulfonylurea-induced severe hypoglycaemia in an older adult requires hospital admission for 24–48h glucose monitoring and immediate deprescribing of the Sulfonylurea
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.2] Sitagliptin Phosphate — Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Gliptin); Incretin Enha
- [4.3] Vildagliptin — Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Cyanopyrrolidine Glipti
- [4.4] Teneligliptin Hydrobromide Hydrate — Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Peptidomimetic Gliptin)
- [4.5] Glimepiride — Second/Third-Generation Sulfonylurea; Pancreatic Beta-Cell Insuli
